Jennifer L Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4107371/publications.pdf

Version: 2024-02-01

1478505 1474206 9 255 9 6 citations h-index g-index papers 9 9 9 334 docs citations times ranked citing authors all docs

| # | Article | IF | Citations |
|---|--|-----|-----------|
| 1 | Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab. BioDrugs, 2016, 30, 321-338. | 4.6 | 84 |
| 2 | Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs, 2018, 10, 678-691. | 5.2 | 62 |
| 3 | In vitro methionine oxidation of recombinant human leptin. Pharmaceutical Research, 1998, 15, 632-640. | 3.5 | 45 |
| 4 | A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501. Advances in Therapy, 2019, 36, 1833-1850. | 2.9 | 24 |
| 5 | Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product. Biologicals, 2020, 68, 79-91. | 1.4 | 14 |
| 6 | Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product. Pharmaceutical Research, 2020, 37, 114. | 3.5 | 13 |
| 7 | Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product. BioDrugs, 2021, 35, 563-577. | 4.6 | 6 |
| 8 | Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab. Immunotherapy, 2018, 10, 1011-1021. | 2.0 | 5 |
| 9 | A Review of the Totality of Evidence for the Development and Approval of ABPÂ710 (AVSOLA), an Infliximab Biosimilar. Advances in Therapy, 2022, 39, 44-57. | 2.9 | 2 |